Back to search results

Magnolia Officinalis Supplement for Psoriasis

This study is looking at whether a dietary supplement called Viv, which contains Magnolia officinalis bark extract, can affect immune markers in adults with psoriasis. You could be eligible if you are 18 or older and have stable psoriasis. The study aims to see if Viv changes levels of a specific immune marker (plasma Beta defensin 2) over 12 weeks. This trial is currently unclear on its recruitment status.

Study design
This is an interventional study planning to enroll 100 participants. It will compare Viv to a placebo (an inactive capsule that looks the same).
What's involved
You would take Viv or a placebo daily for 3 months. You would also complete electronic questionnaires and use at-home blood collection kits at the beginning, 1 month, and 3 months.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at 12 weeks, which is the end of the study product/placebo use.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07471048

A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis

Recruiting
NAAges 18+InterventionalBasic science
Sirt3 LLC
~100 participants
Updated 2026-03-13 on ClinicalTrials.gov
What's tested:Oral supplement containing 200mg Magnolia officinalis bark extractPlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Relative change in plasma Beta defensin 2 from baseline
Measured over From baseline to the end of study product/placebo use at 12 weeks

Conditions

Psoriasis

Explore related trials

Psoriasis

Where it's being run

1 sites across 1 states
New Jersey1

Who to contact

Adeeb Rahman, PhD
[email protected]
2013596845
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Male of female, aged 18 years or older at time of consent.
Diagnosis of stable psoriasis affecting for at least 6 months confirmed by a dermatologist.

Exclusion

Able to read and understand English.
Able to read, understand, and provide informed consent.
Able to use a personal smartphone device and download Chloe by People Science.
Able to receive shipment of the product at an address within the United States.
Able to adhere to study protocol (e.g., willing to collect and ship blood samples)
Do not have a personal smartphone, internet access, or unwilling to download Chloe.
Prior treatment with any systemic non-biologic immunosuppressive agents (e.g., methotrexate, cyclosporine, azathioprine) within 8 weeks prior to randomization.
Prior treatment with any systemic biologic therapies (e.g., guselkumab, risankizumab, ustekinumab, secukinumab, brodalumab, infliximab, adalimumab, golimumab, etanercept) within 6 months prior to randomization
Prior treatment with any other systemic investigational drugs within 6 months prior to randomization.
Other Illnesses or Conditions: Participants who have the following comorbidities or gastrointestinal illnesses are excluded:
Currently pregnant, planning to become pregnant in the next 3 months, or breastfeeding
Any underlying medical conditions or comorbidities that may confound the assessment of digestive symptoms or the evaluation of the study outcomes.
Have a significant illness, disease or condition which, in the opinion of the principal investigator, may impact their ability to participate in the study or impact the study outcomes.
Known hypersensitivity or previous allergic reaction to magnolia, rice or hypromellose.
Are unlikely for any reason to be able to comply with the trial or considered unsuited for participation in the study by the Principal Investigator.

What this trial measures

  • Relative change in plasma Beta defensin 2 from baselineFrom baseline to the end of study product/placebo use at 12 weeks

    Change in plasma Beta defensin 2 levels between placebo and study product group at 4 weeks and 12 weeks relative to baseline as measured by ELISA